Next Article in Journal
Perspectives on the Use of a Medium-Dose Etoposide, Cyclophosphamide, and Total Body Irradiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation: The Japanese Experience from 1993 to Present
Next Article in Special Issue
Effects of Inflammation and Depression on Telomere Length in Young Adults in the United States
Previous Article in Journal
Microangiopathy in Naifold Videocapillaroscopy and Its Relations to sE- Selectin, Endothelin-1, and hsCRP as Putative Endothelium Dysfunction Markers among Adolescents with Raynaud’s Phenomenon
Previous Article in Special Issue
Risk of Depression and Suicidality among Diabetic Patients: A Systematic Review and Meta-Analysis
Article

Abnormal Brain-Derived Neurotrophic Factor Exon IX Promoter Methylation, Protein, and mRNA Levels in Patients with Major Depressive Disorder

1
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
2
Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
Received: 26 March 2019 / Revised: 24 April 2019 / Accepted: 24 April 2019 / Published: 26 April 2019
(This article belongs to the Special Issue Treatment of Bipolar Depression)
Brain-derived neurotrophic factor (BDNF) exon IX promoter methylation levels, serum BDNF protein levels, and serum mRNA levels were investigated in patients with major depressive disorder (MDD) and healthy controls. Over two years, 51 patients with MDD and 62 healthy controls were recruited. Peripheral blood was drawn from all participants to analyze the BDNF exon IX promoter methylation levels as well as serum BDNF protein and mRNA levels, at baseline and after four weeks of antidepressant treatment. Methylation sequential analysis showed that patients with MDD (n = 39) had a higher methylation level at CpG site 217 and lower methylation levels at CpG site 327 and CpG site 362. Drug responders (n = 25) had a higher methylation level at CpG site 24 and CpG site 324 than the non-responders (n = 11). Patients with MDD had a lower serum BDNF protein and mRNA levels than the healthy controls. In conclusion, these results showed that BDNF exon IX promoter methylation levels, serum BDNF protein level, and serum BDNF mRNA level could contribute to the pathophysiology of a major depressive disorder. View Full-Text
Keywords: brain-derived neurotrophic factor; DNA methylation; major depressive disorder brain-derived neurotrophic factor; DNA methylation; major depressive disorder
Show Figures

Figure 1

MDPI and ACS Style

Hsieh, M.-T.; Lin, C.-C.; Lee, C.-T.; Huang, T.-L. Abnormal Brain-Derived Neurotrophic Factor Exon IX Promoter Methylation, Protein, and mRNA Levels in Patients with Major Depressive Disorder. J. Clin. Med. 2019, 8, 568. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm8050568

AMA Style

Hsieh M-T, Lin C-C, Lee C-T, Huang T-L. Abnormal Brain-Derived Neurotrophic Factor Exon IX Promoter Methylation, Protein, and mRNA Levels in Patients with Major Depressive Disorder. Journal of Clinical Medicine. 2019; 8(5):568. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm8050568

Chicago/Turabian Style

Hsieh, Men-Ting, Chin-Chuen Lin, Chien-Te Lee, and Tiao-Lai Huang. 2019. "Abnormal Brain-Derived Neurotrophic Factor Exon IX Promoter Methylation, Protein, and mRNA Levels in Patients with Major Depressive Disorder" Journal of Clinical Medicine 8, no. 5: 568. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm8050568

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop